Gene expression inhibitors for the treatment of liver fibrosis: drugs under preclinical and early clinical investigation-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Gene expression inhibitors for the treatment of liver fibrosis: drugs under preclinical and early clinical investigation

Published:2023-11-28 Issue:12 Volume:32 Page:1133-1141
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Ocker Matthias¹²³,Neureiter Daniel⁴⁵

Affiliation:

1. Medical Department, Division of Hematology, Oncology, and Cancer Immunology, Campus Charité Mitte, Charité University Medicine Berlin, Berlin, Germany

2. EO Translational Insights Consulting GmbH, Berlin, Germany

3. Tacalyx GmbH, Berlin, Germany

4. Institute of Pathology, Paracelsus Medical University/University Hospital Salzburg (SALK), Salzburg, Austria

5. Cancer Cluster Salzburg, Salzburg, Austria

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2023.2288075

Reference90 articles.

1. Mechanisms of Hepatic Fibrogenesis

2. Liver fibrosis: Common mechanisms and antifibrotic therapies

3. Hepatic fibrosis: Concept to treatment

4. Drug target ontology to classify and integrate drug discovery data

5. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP